A live biotherapeutic product (LBP) is a medicinal product that contains live micro-organisms and is intended to prevent, treat, or cure a disease in humans. Because the active substance is living, development and microbiome therapeutics regulation focus heavily on strain identity, viability, and consistent manufacturing. Below are the most common questions teams ask about definitions, how LBPs differ from probiotics and faecal products, US and EU regulatory pathways, CMC for live biotherapeutics, and typical IND and BLA requirements.
What is a live biotherapeutic product (LBP)?
An LBP is a biological medicinal product in which live micro-organisms are the active ingredient, and the intended use is disease prevention, treatment, or cure. Unlike foods, the product’s clinical purpose drives how it is developed, tested, and regulated.
Typical formats include oral capsules, lyophilised powders, liquids, or rectal delivery forms, depending on the target site and stability needs. Two attributes are central throughout development:
- Strain identity: you must be able to unambiguously define what organism(s) are present, often down to strain level.
- Viability and potency: you must control how many live cells are delivered at release and through shelf-life, and show that this links to the intended biological activity.
For multi-strain products or consortia, the definition expands to include composition control, relative abundance, and stability of the community over time.
How are LBPs different from probiotics and fecal microbiota products?
LBPs differ from probiotics mainly in intended use and claims. Probiotics are typically positioned as foods or supplements that support normal function, while an LBP is developed as a drug or biologic to address a disease indication, which triggers drug-level evidence and controls.
| Category | Primary intent | Typical regulatory framing |
|---|---|---|
| Probiotics | Support normal physiology | Food or supplement (jurisdiction-dependent) |
| LBPs | Prevent, treat, or cure disease | Drug/biologic pathways |
| Faecal microbiota products (e.g., FMT) | Transfer complex donor microbiota | Often treated separately with specific policies |
Faecal microbiota products are usually derived directly from donor material and can be highly variable, whereas LBPs are manufactured with defined composition and controls. Live microbial consortia can be LBPs when they are defined, manufactured, and clinically developed for a disease indication.
How are live biotherapeutic products regulated in the US and EU?
In the US, LBPs are generally regulated by the FDA under drug/biologic frameworks. Development commonly starts with an IND, followed by clinical phases, and may culminate in a BLA or other marketing application, depending on classification. FDA LBP guidance concepts emphasise identity, purity, potency, and safety for living organisms, plus appropriate cGMP controls.
In the EU, regulatory routes depend on product classification and claims, and may involve national competent authorities and EMA-linked procedures for certain categories. Requirements often align with medicinal product expectations: robust quality data, nonclinical safety, and well-controlled clinical evidence.
Because microbiome therapeutics regulation can vary by jurisdiction and product specifics, teams typically confirm classification early and align CMC and clinical plans to the intended pathway. This is general information, not legal advice.
What quality and manufacturing controls are required for LBPs?
CMC for live biotherapeutics centres on proving that every batch contains the intended organism(s), at the intended potency, with controlled risks from contaminants and genetic drift. The goal is a consistent product that remains viable and fit for use through shelf-life.
- Strain characterisation: taxonomy, strain typing, and key phenotypic traits relevant to function and safety.
- Identity, purity, potency: validated methods for confirming what is present, what is absent, and how activity is measured (often including viable count).
- Genetic stability: controls and monitoring to manage mutations across passages and scale-up.
- Contamination control: adventitious agents, bacteriophages, and unwanted microbes, with environmental monitoring and raw material controls.
- Process validation: fermentation, harvest, formulation, and fill-finish steps shown to be reproducible.
- Storage and shelf-life: stability programmes defining temperature, packaging, transport, and acceptable potency loss.
- Lot release: predefined specifications and acceptance criteria tied to clinical material comparability.
What preclinical and clinical evidence is needed to develop an LBP?
LBP evidence packages usually combine nonclinical safety with clinical proof of benefit in the target indication. Nonclinical work focuses on risks specific to live organisms, while clinical development follows standard phase progression with endpoints aligned to the disease and mechanism.
Common nonclinical elements include:
- Safety profiling: toxicity signals, local tolerance, and immunological considerations where relevant.
- Biodistribution and persistence: where the organism goes, how long it persists, and whether it translocates.
- Antibiotic resistance and virulence factors: genomic and phenotypic screening, plus risk mitigation plans.
- Mechanism-of-action support: evidence linking microbial activity to functional outputs (metabolites, community shifts) that justify endpoints and dosing rationale.
Clinically, teams typically move from safety and dose-finding to controlled efficacy studies, while maintaining comparability between clinical and commercial manufacturing. A strong dossier connects CMC controls, nonclinical safety, and clinical outcomes into a coherent, risk-based argument.
How Cryptobiotix helps with live biotherapeutic product regulation?
Cryptobiotix supports live biotherapeutic product (LBP) programmes by generating mechanistic and translational evidence with an ex vivo gut microbiome workflow, helping teams make earlier, better-supported decisions for microbiome therapeutics regulation.
- Mechanism-of-action packages using the SIFR® technology, including microbiome composition and metabolite readouts relevant to LBP activity.
- Assessment of inter-individual variability across donor cohorts to inform responder logic and clinical strategy.
- Host-relevant follow-on testing to connect microbial modulation to functional signals that strengthen regulatory narratives.
- Study designs aligned to product goals across sectors described on our applications page.
- Supporting documentation expectations, with access to our scientific evidence overview for due diligence discussions.
If you want to map your evidence plan to IND and BLA requirements and de-risk CMC for live biotherapeutics with targeted preclinical data, contact us via the contact page.
Key takeaways for development teams
- LBPs are regulated as medicines because they are intended to prevent, treat, or cure disease.
- Regulatory success depends on tight control of identity, viability, and manufacturing consistency.
- Preclinical packages should address live-organism risks and provide mechanism-of-action support that aligns with clinical endpoints.
